Halyna Pylypenko

Cherkasy, Ukraine

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea/best available therapy (PROUD-PV/CONTINUATION-PV).

Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea/best available therapy (PROUD-PV/CONTINUATION-PV).

Journal: HemaSphere
Published: January 28, 2025

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.

Journal: Leukemia
Published: May 15, 2023

The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.

The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.

Journal: Nature medicine
Published: January 25, 2023

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b.

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b.

Journal: Leukemia
Published: December 25, 2021

Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.

Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.

Journal: American journal of hematology
Published: August 22, 2021

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.

Journal: American journal of hematology
Published: March 22, 2021

Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.

Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.

Journal: American journal of hematology
Published: March 09, 2021

Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.

Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.

Journal: Journal of hematology & oncology
Published: March 03, 2021

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.

Journal: Lancet (London, England)
Published: May 26, 2020

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups.

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups.

Journal: HemaSphere
Published: April 14, 2020

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.

Journal: The Lancet. Haematology
Published: July 23, 2019

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.

Journal: The Lancet. Oncology
Published: August 02, 2018
Showing 1-12 of 20

Last Updated: 09/26/2026